# Tadalafil

Drug · id `cardio:tadalafil` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: ADCIRCA; ALYQ

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Tadalafil, in the forms sold as Adcirca and Alyq for pulmonary arterial hypertension (PAH), is a phosphodiesterase 5 (PDE5) inhibitor. The US labels of both products list treating PAH (WHO Group 1) to improve exercise ability. This page covers the pulmonary arterial hypertension use. Tadalafil also has a separate US label for erectile dysfunction and for benign prostatic hyperplasia, which this page does not describe. The label says tadalafil inhibits PDE5, the enzyme that breaks down cyclic guanosine monophosphate.

## Technical summary

RxNorm ingredient 358263; UNII 742SXX0ICT. MeSH D000068581 is Tadalafil, with Cialis among its entry terms (a lookup on 2026-11-18, hash only), and carries no scope note, so it is recorded as an exact match for identity only. RxClass lists the established pharmacologic class Phosphodiesterase 5 Inhibitor, so the record is filed under the PDE5 inhibitor page for pulmonary hypertension. The labels read are Adcirca (United Therapeutics Corporation, NDA022332, effective 2025-12-15 in openFDA) and Alyq (Teva Pharmaceuticals, Inc., ANDA216932, effective 2023-04-01). The Cialis label (NDA021368, effective 2026-06-03) was read only for its indication sentences. Drugs@FDA also holds fixed combinations with another ingredient, which a single-ingredient match would not include; they were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients with pulmonary arterial hypertension, as described in the US labels of Adcirca and Alyq

Recipient: Recipient not specified; Population: Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the labels state. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Adcirca (tadalafil, United Therapeutics Corporation, application NDA022332; the version dated 2025-12-15 in openFDA) calls the medicine a phosphodiesterase 5 (PDE5) inhibitor. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. The US label of Alyq (tadalafil tablets, Teva Pharmaceuticals, Inc., application ANDA216932; the version dated 2023-04-01 in openFDA) lists the same use.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the labels state. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim is tied to the two pulmonary arterial hypertension labels named. The substance also has separate labels for other uses, which are not recorded here. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22ff61b237-be8e-461b-8114-78c52a8ad0ae%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:37Z. Source state: Current. Version fingerprint: 842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532.
     How it applies: Application number of the label read, NDA022332.
  2. Background: openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22ff61b237-be8e-461b-8114-78c52a8ad0ae%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:37Z. Source state: Current. Version fingerprint: 842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532.
     How it applies: Effective date of the label text read, 20251215.
  3. Supports: openFDA drug label record for Adcirca (tadalafil tablets), United Therapeutics Corporation label: indication wording and mechanism (class page) (Regulator, edition The openFDA drug label record for set id ff61b237-be8e-461b-8114-78c52a8ad0ae (manufacturer United Therapeutics Corporation, application NDA022332), returned on 2026-11-18. The label text is dated 2025-12-15 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22ff61b237-be8e-461b-8114-78c52a8ad0ae%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:37Z. Source state: Current. Version fingerprint: 842c342248c8be4ffaa382bf9f35083a88a1f4e85dc21f70e1ccd15ee9129532.
     How it applies: Label passage quoted in the research quote table (Q-K30-TAD-LB-04).
  4. Background: openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications (Regulator, edition The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%222faa7a55-3054-456b-8465-6ea6dc1c0aa9%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-19T02:47:47Z. Source state: Current. Version fingerprint: 47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff.
     How it applies: Application number of the Alyq label read, ANDA216932.
  5. Background: openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications (Regulator, edition The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%222faa7a55-3054-456b-8465-6ea6dc1c0aa9%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-19T02:47:47Z. Source state: Current. Version fingerprint: 47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff.
     How it applies: Effective date of the Alyq label text read, 20230401.
  6. Supports: openFDA drug label record for Alyq (tadalafil tablets, USP), Teva Pharmaceuticals, Inc. label: indications (Regulator, edition The openFDA drug label record for set id 2faa7a55-3054-456b-8465-6ea6dc1c0aa9 (manufacturer Teva Pharmaceuticals, Inc., application ANDA216932), returned on 2026-11-18. The label text is dated 2023-04-01 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%222faa7a55-3054-456b-8465-6ea6dc1c0aa9%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-19T02:47:47Z. Source state: Current. Version fingerprint: 47997986bf19175c15349dd70340939659f81639a533059b7758bd2fdb5c7cff.
     How it applies: Label passage quoted in the research quote table (Q-K30-TAD-AL-03).

## Connected pages

- Tadalafil is a phosphodiesterase 5 inhibitor (FDA established pharmacologic class in RxClass): PDE5 inhibitors for pulmonary hypertension (`cardio:pde5-inhibitors-for-pulmonary-hypertension`)
- FDA labels for Adcirca and Alyq list pulmonary arterial hypertension (WHO Group 1), to improve exercise ability, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-adcirca-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)
- Related to: Ambrisentan (`cardio:ambrisentan`)
- Related to: Endothelin receptor antagonists (`cardio:endothelin-receptor-antagonists`)
- Related to: Macitentan (`cardio:macitentan`)

## Provenance

Content hash: 20c74684d9a65f914c36826b968c3e21da91299b721d5eeb9c8023d1c33fa923
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
